Piramal Pharma Q1: Loss Narrows, Margins Improve

📌 Piramal Pharma Q1 FY26 Results Net Loss: ₹694M vs ₹817M (YoY) ⬇️ Revenue: ₹22.7B vs ₹19.33B (YoY) ⬆️ EBITDA: ₹1.95B vs ₹1.07B (YoY) ⬆️ EBITDA Margin: 8.6% vs 5.5% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹85B Net Loss: ~₹3.2B Debt-to-Equity: ~0.7 P/E Ratio: Negative (loss-making) ROE: Negative Dividend Yield: Nil ⚠️ Risks Persistent losses Moderate debt levels Regulatory challenges Competitive intensity Margin sustainability